| Title |
Epigenetics, Autism Spectrum, and Neurodevelopmental Disorders
|
|---|---|
| Published in |
Neurotherapeutics, October 2013
|
| DOI | 10.1007/s13311-013-0227-0 |
| Pubmed ID | |
| Authors |
Sampathkumar Rangasamy, Santosh R. D'Mello, Vinodh Narayanan |
| Abstract |
Epigenetic marks are modifications of DNA and histones. They are considered to be permanent within a single cell during development, and are heritable across cell division. Programming of neurons through epigenetic mechanisms is believed to be critical in neural development. Disruption or alteration in this process causes an array of neurodevelopmental disorders, including autism spectrum disorders (ASDs). Recent studies have provided evidence for an altered epigenetic landscape in ASDs and demonstrated the central role of epigenetic mechanisms in their pathogenesis. Many of the genes linked to the ASDs encode proteins that are involved in transcriptional regulation and chromatin remodeling. In this review we highlight selected neurodevelopmental disorders in which epigenetic dysregulation plays an important role. These include Rett syndrome, fragile X syndrome, Prader-Willi syndrome, Angelman syndrome, and Kabuki syndrome. For each of these disorders, we discuss how advances in our understanding of epigenetic mechanisms may lead to novel therapeutic approaches. |
Mendeley readers
The data shown below were compiled from readership statistics for 202 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | <1% |
| Portugal | 1 | <1% |
| Brazil | 1 | <1% |
| Netherlands | 1 | <1% |
| United States | 1 | <1% |
| Croatia | 1 | <1% |
| Unknown | 195 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 34 | 17% |
| Student > Bachelor | 29 | 14% |
| Student > Ph. D. Student | 28 | 14% |
| Researcher | 24 | 12% |
| Student > Doctoral Student | 11 | 5% |
| Other | 30 | 15% |
| Unknown | 46 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 39 | 19% |
| Medicine and Dentistry | 26 | 13% |
| Biochemistry, Genetics and Molecular Biology | 20 | 10% |
| Psychology | 19 | 9% |
| Neuroscience | 18 | 9% |
| Other | 26 | 13% |
| Unknown | 54 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 October 2013.
All research outputs
#17,489,487
of 25,654,806 outputs
Outputs from Neurotherapeutics
#1,069
of 1,316 outputs
Outputs of similar age
#139,086
of 220,542 outputs
Outputs of similar age from Neurotherapeutics
#11
of 13 outputs
Altmetric has tracked 25,654,806 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,316 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.4. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 220,542 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.